New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

There are several drugs for type 2 diabetes that focus on driving cells to secrete more insulin, and there are standard treatments centered around improving blood sugar control, weight loss, high ...

Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority ...

The treatment led to an average 20 per cent weight loss in people living with obesity alone and a nearly 17 per cent mean weight loss in those living with obesity and type 2 diabetes, the study found.

A new oral drug may be able to treat type 2 diabetes and obesity without impacting muscle mass as an alternative to GLP-1 drugs such as Ozempic, the results of a phase 1 clinical trial suggest.

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in people with the condition, finds the largest study ...

A drug used to treat type 2 diabetes may also be used to treat prostate cancer. The corresponding study was published in Molecular Cancer. "This is a significant discovery. For the first time, we have ...

He noted, for instance, that Ozempic and other new drugs used to treat type 2 diabetes are also able to inhibit AgRP neurons. The extent to which this effect contributes to the antidiabetic action ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs ...

April 14 (UPI) -- The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to treat Type 2 diabetes, have been found in the United States.

Dapagliflozin, a SGLT2 inhibitor used for type 2 diabetes, alleviates steatohepatitis and fibrosis in patients with progressive liver disease, a recent clinical trial shows.